Inclusion Criteria for all Modules:

          1. Metastatic MIBC

          2. 2nd/3rd line

          3. Failed adjuvant/neo-adjuvant chemotherapy <1 yr

          4. 1 lesion ≥10 mm at baseline in the longest diameter suitable for accurate repeated
             measurement

          5. WHO perf. status 0-1

        For Module A:

          1. M/F ≥25

          2. Confirmation of FGFR3 mutation or FGFR fusion

        For Module B:

          1. Hgb ≥10 g/dL

          2. Deleterious mutation, deletion or truncation in any HRR genes

        For Module C:

        1. Tumour harbours a deletion or inactivating mutation of the CDKN2A or RB1 genes and/or
        amplification of CCNE1, MYC, MYCL or MYCN genes

        For Module E:

        1. Contraception must be sustained throughout treatment with vistusertib and 16 wks after
        last dose

        For Module F:

          1. Adequate organ and marrow function, defined as Leukocytes ≥3.0x10(exp9)/L; ANC
             ≥1.5x10(exp9)/L; platelets ≥100x10(exp9)/L

          2. Contraceptive measures must be sustained throughout treatment with AZD9150 and for 180
             days after the last dose.

        Exclusion Criteria for all Modules:

          1. Immunotherapy, chemotherapy, anticancer agents, radiotherapy <4 weeks, or radiotherapy
             for palliation <2 weeks, any study drugs <30 days.

          2. Major surgery <4 weeks

          3. Unresolved toxicities from prior therapy

          4. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy

          5. Immunosuppressive drugs <28 days

          6. Any of the following: Autoimmune disease ≤2 yr; IBD; primary immunodeficiency; organ
             transplant requiring immunosuppressives

          7. Spinal cord compression or brain metastases, treated and stable & not requiring
             steroids for at least 4 weeks

          8. Severe or uncontrolled systemic disease

          9. Any of the following: Mean QTc ≥470 ms; abnormalities in resting ECG; factors that
             increase the risk of QTc prolongation or arrhythmia; uncontrolled hyper/hypotension;
             LVEF <55%; atrial fibrillation; NYHA Grade II-IV; severe valvular disease;
             uncontrolled angina; stroke/TIA <6 months; acute coronary syndrome <6 months

         10. Any of the following laboratory values: ANC <1.5x10(exp9)/L; Platelets
             <100x10(exp9)/L; Hgb <9.0 g/dL; ALT >2.5xULN or >5xULN with liver mets; Total
             bilirubin >1.5 times ULN or with Gilbert's disease ≥2×ULN; Creatinine >1.5xULN
             concurrent with creatinine clearance <50 mL/min; Corrected Ca >ULN, PO4 >ULN

         11. Active infection including tuberculosis, hepatitis B (HBV), hepatitis C (HCV), or
             human immunodeficiency virus. Patients with a past or resolved HBV infection are
             eligible. Patients positive for HCV antibody are eligible only if polymerase chain
             reaction is negative for HCV RNA.

         12. Live attenuated vaccination <30 days

        For Module A:

          1. Prior exposure to: Nitrosourea or mitomycin C <6 weeks; any agent with FGFR inhibition
             as its primary pharmacology; AZD4547; potent inhibitors/inducers of CYP3A4, inhibitors
             of CYP2D6 or substrates of CYP3A4 <2 wks

          2. Ophthalmological criteria: RPED; laser treatment or intraocular injection for macular
             degeneration; age-related macular degeneration; retinal vein occlusion; retinal
             degenerative disease; other clinically relevant chorioretinal defect

          3. Refractory nausea/vomiting, chronic GI diseases, or previous bowel resection

        For Module B:

          1. Transfusion <120 days

          2. Concurrent medications that are strong inhibitors of cytochrome P450 (CYP) 3A (CYP3A)
             or strong inducers of CYP3A4.

          3. Previous treatment with PARP inhibitor, including olaparib

          4. Patients with history of MDS or AML

        For Module C:

          1. Prior exposure to any of the following: Nitrosourea or mitomycin C <6 wks; any agent
             with Wee1 inhibition as its primary pharmacology; prior treatment with AZD1775

          2. Any drugs or products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates
             with narrow therapeutic index, or moderate to strong inhibitors/inducers of CYP3A4

          3. Herbal preparations

          4. Refractory nausea and vomiting or chronic GI diseases

          5. Cardiac disease <6 months

        For Module E:

          1. Minor surgery <14 days of first dose

          2. Exposure to specific substrates of OATP1B1, OATP1B3, MATE1 and MATE2K <5x half-life
             before treatment. Exposure to strong/moderate inhibitors/inducers of CYP3A4/5, Pgp
             (MDR1) and BRCP if taken within washout periods before the first dose

          3. Haemopoietic growth factors (filgrastim, sargramostim, GM-CSF) <14 days prior to
             treatment

          4. Other mTOR inhibitors

          5. Renal disease or renal tubular acidosis

          6. Uncontrolled Type 1 or 2 diabetes

        For Module F:

        1. AST ≤ 2.5xULN or ≤5xULN with liver metastases

        For Module G:

          1. Have had prior treatment with a MEK, Ras or Raf inhibitor.

          2. Any of the following ophthalmic criteria: Current or past history of central serous
             retinopathy, detachment of retinal pigmented epithelium, or retinal vein occlusion;
             intraocular pressure (IOP) >21 mmHg; uncontrolled glaucoma (irrespective of IOP)

          3. Baseline left ventricular ejection fraction (LVEF) <55% measured by echocardiogram
             (ECHO) or, if allowed, a multigated acquisition (MUGA) scan. Appropriate correction to
             be used if a MUGA is performed.

          4. Previous moderate or severe impairment of LVEF (<45% on echocardiography or equivalent
             on MUGA) even if full recovery has occurred.

          5. Male or female patients with reproductive potential and, as judged by the
             investigator, are not employing an effective method of birth control and female
             patients who are breastfeeding.

          6. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation
             pneumonitis which required steroid treatment, or any evidence of clinically active
             ILD.

          7. Receiving or have received systemic therapy with nitrosoureas, mitomycin or suramin
             within 6 weeks prior to starting study treatment.